Bone drug switch: can alendronate and zoledronate keep bones strong after denosumab?

NCT ID NCT05091099

Completed Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the best way to prevent bone loss after stopping denosumab, a common osteoporosis treatment. Researchers tested giving alendronate first, then zoledronate, versus zoledronate alone in 44 postmenopausal women and men over 50. The goal was to see which approach better maintains bone density and reduces fracture risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alendronate and zoledronate (bisphosphonate drugs)
What this could lead to: If it works, this could provide a clear treatment plan to maintain bone strength after stopping denosumab, reducing fracture risk.
What could go wrong: This is a small, single-center study with only 44 participants, so results may not apply to everyone. The drugs may not fully prevent bone loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS

Contacts and locations

Locations

National Taiwan University Hospital, Yunlin branch

Douliu, Yunlin County, 640, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.